secwatch / observer
8-K filed May 2, 2025, 7:59 PM ET ticker PALI CIK 0001357459
regulatory confidence high sentiment negative materiality 0.55

PALISADE BIO, INC. (PALI): Nasdaq/NYSE listing notice — Palisade Bio receives Nasdaq deficiency notice for bid price below $1.00

PALISADE BIO, INC.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PALISADE BIO, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange
nasdaq
Notice
deficiency notice
Deficiency
minimum bid price
Rules
5550(a)(2)
Exact text from the filing
April 30, 2025, Palisade Bio, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that for 30 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no effect on the listing of the Company’s common stock at this time, and the Company’s common stock continues to trade on The Nasdaq Cap
View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

PALISADE BIO, INC. filing history →

Source: SEC EDGAR
accession 0001641172-25-008346
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.